Journal Logo

CE Connection

New Drugs 2020, part 1

Author Information
doi: 10.1097/
  • Free

INSTRUCTIONS New Drugs 2020, part 1


  • Read the article. The test for this CE activity is to be taken online at
  • You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
  • There's only one correct answer for each question. A passing score for this test is 13 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
  • For questions, contact Lippincott Professional Development: 1-800-787-8985.
  • Registration deadline is December 3, 2021.


Lippincott Professional Development will award 1.5 contact hours and 1.5 pharmacology credits for this continuing nursing education activity. Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours, and the District of Columbia, Georgia, and Florida CE Broker #50-1223.

Payment: The registration fee for this test is $17.95.

New Drugs 2020, part 1

GENERAL PURPOSE: To provide information about seven drugs recently approved by the FDA. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Describe indications for seven newly approved drugs. 2. Identify nursing implications for these new drugs.

  1. Which statement is correct about prucalopride?
    1. It is indicated to treat CIC in adults and children.
    2. It is a 5-HT4 receptor antagonist.
    3. It acts as a gastrointestinal prokinetic agent to stimulate colonic peristalsis.
  2. Prucalopride is contraindicated in patients
    1. taking MAO inhibitors.
    2. with Crohn disease.
    3. with COPD.
  3. Istradefylline is thought to treat “off” episodes of Parkinson disease by
    1. acting as a serotonin agonist.
    2. antagonizing adenosine A2A receptors.
    3. raising dopamine levels in the brain.
  4. The most common reason for discontinuation of istradefylline in clinical trials was
    1. dyskinesia.
    2. hypertension.
    3. gastrointestinal bleeding.
  5. If a patient develops psychotic behavior during treatment with istradefylline, the practitioner should
    1. consider reducing the dosage or discontinuing treatment.
    2. add a mood stabilizer to the medication regimen.
    3. add an antipsychotic drug to the medication regimen.
  6. Solriamfetol is
    1. a dopamine and norepinephrine reuptake inhibitor.
    2. used to treat airway obstruction in patients with OSA.
    3. an adenosine and epinephrine receptor antagonist.
  7. The recommended starting dose of solriamfetol for patients with OSA is
    1. 37.5 mg/day.
    2. 75 mg/day.
    3. 150 mg/day.
  8. Advise patients starting treatment with solriamfetol that
    1. hepatic function will be regularly monitored throughout treatment.
    2. the daily dose should be taken right before bed.
    3. this drug is a federally controlled substance with potential for abuse.
  9. Pitolisant is indicated to treat
    1. excessive daytime sleepiness in patients with OSA.
    2. excessive daytime sleepiness in adults with narcolepsy.
    3. airway obstruction in patients with OSA.
  10. Which statement about pitolisant is correct?
    1. It is classified as a controlled substance.
    2. Studies have shown that it is safe for use during pregnancy.
    3. It may prolong the QT interval.
  11. Pitolisant is contraindicated in patients with
    1. intestinal inflammatory disorders.
    2. severe hepatic impairment.
    3. mild to moderate renal impairment.
  12. Omadacycline was developed to
    1. treat viral respiratory infections in patients with COPD.
    2. be used as a first-line treatment for CABP.
    3. overcome bacterial resistance to tetracyclines.
  13. During treatment with omadacycline, patients should be monitored for
    1. obsessive-compulsive behavior.
    2. C. difficile-associated diarrhea.
    3. QT prolongation.
  14. Teach patients with CABP taking oral omadacycline that
    1. the dosage will be increased over the first 3 days of administration.
    2. each dose should be taken with food to prevent nausea.
    3. dairy products should not be consumed for at least 4 hours after taking a dose.
  15. Which statement about sarecycline is correct?
    1. It has anti-inflammatory and antibacterial properties.
    2. It is indicated to treat ABSSSI.
    3. It is indicated for concurrent use with oral retinoids.
  16. Which of the following is an adverse reaction to sarecycline?
    1. hypotension
    2. upper respiratory tract infection
    3. nausea
  17. The primary action of romosozumab is to
    1. stimulate osteoblastic activity.
    2. inhibit bone resorption.
    3. inhibit osteoblastic activity.
  18. Romosozumab is administered
    1. orally.
    2. subcutaneously.
    3. I.V.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.